Table 3 Susceptibility of isolated viruses to FAV.
Group number | Treatment with | Days post infection | IC50 valuea (μg/ml) |
|---|---|---|---|
3 | FAV | 28b | 2.3 |
| Â | Â | 28 | 2.1 |
| Â | Â | 28 | 1.6 |
| Â | Â | 38 | 2.0 |
| Â | Â | 38 | 1.7 |
| Â | Â | 42 | 1.7 |
| Â | Â | 43 | 2.3 |
6 | FAV + Anti-Stem mAb | 28 | 1.8 |
| Â | Â | 28 | 1.7 |
| Â | Â | 28 | 2.0 |
| Â | Â | 51 | 1.9 |
| Â | Â | 117 | 1.8 |
| Â | Â | 122 | 2.3 |
| Â | Â | 138 | 2.3 |
7 | FAV + Anti-RBS mAb | 28 | NAc |
| Â | Â | 28 | NA |
| Â | Â | 28 | NA |
| Â | Â | 51 | 1.1 |
| Â | Â | 58 | 4.7 |
| Â | Â | 85 | 1.1 |
| Â | Â | 100 | 2.3 |